Story perspectives

Medicare Reimburses GENFIT NASHnext Test $252 Starting 2026

7/3/2026

Summary

Story summary

Medicare will reimburse GENFIT’s NASHnext® test at $252 beginning August 10, 2026.
The test measures disease activity and stage 2 fibrosis to identify at-risk MASH patients.
Reimbursement follows Current Procedural Terminology (CPT) 0468U on the Clinical Laboratory Fee Schedule for qualifying Medicare patients.
GENFIT expects coverage to raise adoption and revenue, noting that Dr. Naim Alkhouri and Prof. Kenneth Cusi say the reimbursement will improve access and aid treatment decisions.

1 of 1

Story summary

Medicare will reimburse GENFIT’s NASHnext® test at $252 beginning August 10, 2026.
The test measures disease activity and stage 2 fibrosis to identify at-risk MASH patients.
Reimbursement follows Current Procedural Terminology (CPT) 0468U on the Clinical Laboratory Fee Schedule for qualifying Medicare patients.
GENFIT expects coverage to raise adoption and revenue, noting that Dr. Naim Alkhouri and Prof. Kenneth Cusi say the reimbursement will improve access and aid treatment decisions.